Teva Pharmaceuticals CEO on Q3 Earnings Beat and Biopharma Transformation

Q3 Performance and Growth Drivers

• 📈 Teva Pharmaceuticals reported a Q3 earnings beat, driven significantly by its innovative branded drug portfolio, which grew by 33%.
• 🎯 The company's strategic shift from a primarily generics company to a biopharma company is showing strong results, with specific treatments experiencing substantial growth.
• 💡 Key growth areas include treatments for schizophrenia (up 24%) and migraine (up 19%), indicating strong market demand and competitive positioning.

Inflation Reduction Act (IRA) and ETO

• 🤝 Teva finalized discussions with CMS regarding pricing for its Huntington's disease and tardive dyskinesia treatment, ETO, under the Inflation Reduction Act.
• 📊 The negotiated price came in line with Teva's 2023 forecast, providing market confidence and removing uncertainty.
• 🚀 This clarity supports Teva's confidence in ETO achieving $2.5 billion in sales by 2027 and over $3 billion in peak sales.

Schizophrenia and Migraine Treatment Success

• 🧠 The schizophrenia treatment's success is attributed to its efficacy as a long-acting subcutaneous injection that quickly reaches therapeutic levels, addressing a significant unmet need.
• 🌟 Teva is further strengthening its schizophrenia franchise with another long-acting treatment planned for launch next year, targeting $1.5 to $2 billion in peak sales.
• 🏆 In the competitive migraine market, Teva's Ajobi brand continues to grow at 19%, demonstrating the company's ability to compete effectively against larger pharmaceutical companies.

Future Outlook and Innovation Pipeline

• 🚀 Teva's